Skip to main content

J&J: Potential HIV vaccine falls short in mid-stage study

A potential HIV vaccine being developed by Johnson & Johnson did not provide protection against the virus in a mid-stage study, the drugmaker said Tuesday.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.